Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
VEGF
brain metastases
docetaxel plus ramucirumab
non-small cell lung cancer
sVEGFR-2
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
02 06 2023
02 06 2023
Historique:
received:
12
10
2022
accepted:
03
01
2023
medline:
8
6
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety for patients with brain metastases are still unclear. Eligible patients included those with advanced NSCLC with measurable asymptomatic brain metastases that progressed after chemotherapy. Patients were intravenously administered ramucirumab (10 mg/kg) and docetaxel (60 mg/m2) every 21-day cycle. Due to difficulties in accumulating the planned 65 participants, enrollment was terminated early when 25 patients were enrolled. Primary endpoint: Median progression-free survival (PFS) was 3.9 months (95% CI, 1.8-5.3). Secondary endpoints: Median intracranial progression-free survival was 4.6 months (95% CI, 2.5-5.9); median overall survival was 20.9 months (95% CI, 6.6-not possible to estimate); objective response rate was 20% (95% CI, 6.8-40.7); disease control rate was 68% (95% CI, 46.5-85.1). The most common grade 3 or higher toxicities were neutropenia in 10 patients (40%). Neither intracranial hemorrhage nor grade 5 adverse events were observed. Patients with higher serum soluble vascular endothelial growth factor receptor 2 concentrations at the start of treatment had slightly longer PFS. No clinical concerns were identified with DOC/RAM for NSCLC with brain metastases in this study. Further investigation with a larger sample size is needed to determine the tolerability and safety of these populations (Trial Identifiers: University Hospital Medical Information Network in Japan [UMIN000024551] and Japan Registry of Clinical Trials [jRCTs071180048]).
Sections du résumé
BACKGROUND
Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety for patients with brain metastases are still unclear.
METHODS
Eligible patients included those with advanced NSCLC with measurable asymptomatic brain metastases that progressed after chemotherapy. Patients were intravenously administered ramucirumab (10 mg/kg) and docetaxel (60 mg/m2) every 21-day cycle.
RESULTS
Due to difficulties in accumulating the planned 65 participants, enrollment was terminated early when 25 patients were enrolled. Primary endpoint: Median progression-free survival (PFS) was 3.9 months (95% CI, 1.8-5.3). Secondary endpoints: Median intracranial progression-free survival was 4.6 months (95% CI, 2.5-5.9); median overall survival was 20.9 months (95% CI, 6.6-not possible to estimate); objective response rate was 20% (95% CI, 6.8-40.7); disease control rate was 68% (95% CI, 46.5-85.1). The most common grade 3 or higher toxicities were neutropenia in 10 patients (40%). Neither intracranial hemorrhage nor grade 5 adverse events were observed. Patients with higher serum soluble vascular endothelial growth factor receptor 2 concentrations at the start of treatment had slightly longer PFS.
CONCLUSION
No clinical concerns were identified with DOC/RAM for NSCLC with brain metastases in this study. Further investigation with a larger sample size is needed to determine the tolerability and safety of these populations (Trial Identifiers: University Hospital Medical Information Network in Japan [UMIN000024551] and Japan Registry of Clinical Trials [jRCTs071180048]).
Identifiants
pubmed: 37053467
pii: 7117810
doi: 10.1093/oncolo/oyad013
pmc: PMC10243767
doi:
Substances chimiques
Docetaxel
15H5577CQD
Vascular Endothelial Growth Factor A
0
Banques de données
UMIN-CTR
['UMIN000024551']
JPRN
['jRCTs071180048']
Types de publication
Clinical Trial, Phase II
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
551-e454Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803
pubmed: 10098435
Clin Cancer Res. 2015 Apr 15;21(8):1896-903
pubmed: 25614446
Anticancer Res. 2016 Jun;36(6):2939-44
pubmed: 27272808
Angiogenesis. 1999;3(1):33-9
pubmed: 14517442
J Thorac Dis. 2019 Nov;11(11):4725-4734
pubmed: 31903262
Lung Cancer. 2011 Nov;74(2):326-31
pubmed: 21481963
Ann Oncol. 2018 Mar 1;29(3):602-609
pubmed: 29228087
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
Oncology. 2018;94(1):55-64
pubmed: 29065416
Clin Cancer Res. 2008 Dec 1;14(23):7871-7
pubmed: 19047116
Cancer Res. 2000 Sep 1;60(17):4959-67
pubmed: 10987313
Lung Cancer. 2016 Sep;99:186-93
pubmed: 27565938
Br J Cancer. 2013 Mar 19;108(5):1052-60
pubmed: 23422754
Oncol Lett. 2010 Mar;1(2):253-259
pubmed: 22966290
J Clin Oncol. 2010 Feb 10;28(5):780-7
pubmed: 20048182
Oncotarget. 2016 Jan 19;7(3):3635-44
pubmed: 26498354
Neurooncol Adv. 2020 Mar 16;2(1):vdaa038
pubmed: 32642693
Eur J Cancer. 2020 Mar;127:150-157
pubmed: 32014812
Clin Exp Metastasis. 2004;21(2):107-18
pubmed: 15168728